Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

15 trials with published results (16%)

Research Maturity

59 completed trials (61% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

8.3%

8 terminated out of 96 trials

Success Rate

88.1%

+1.5% vs benchmark

Late-Stage Pipeline

21%

20 trials in Phase 3/4

Results Transparency

25%

15 of 59 completed with results

Key Signals

15 with results88% success

Data Visualizations

Phase Distribution

62Total
Not Applicable (32)
Early P 1 (1)
P 1 (3)
P 2 (6)
P 3 (8)
P 4 (12)

Trial Status

Completed59
Unknown20
Terminated8
Recruiting6
Withdrawn3

Trial Success Rate

88.1%

Benchmark: 86.5%

Based on 59 completed trials

Clinical Trials (96)

Showing 20 of 20 trials
NCT05309785Phase 4CompletedPrimary

Safety and Efficacy of Canagliflozin in Advanced CKD

NCT05434325Completed

TESTING -ON Post-Trial ObservatioNal Cohort Study

NCT03276390Not ApplicableCompletedPrimary

A Culturally Targeted Transplant Program

NCT03242343Not ApplicableCompleted

VasQ External Support for Arteriovenous Fistula

NCT05879302Not ApplicableCompleted

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

NCT06487546Not ApplicableRecruitingPrimary

Repletion of Ergothioneine in Patients With Kidney Failure

NCT06913647Phase 2RecruitingPrimary

Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

NCT06001827Not ApplicableRecruiting

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

NCT06366230Phase 1Recruiting

Adding Urea to the Final Dialysis Fluid

NCT02513303Phase 3Completed

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

NCT05425056Phase 3Completed

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

NCT00567398Phase 3CompletedPrimary

IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

NCT00567489Phase 4CompletedPrimary

IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

NCT03616535Not ApplicableTerminatedPrimary

Interventions Made to Preserve Cognitive Function

NCT03754361Not ApplicableTerminatedPrimary

The Study of Efficacy and Safety of Automated PD in Urgent Start Dialysis

NCT06466421Phase 4Completed

Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis

NCT05339139Phase 3Recruiting

SAfety of Regional Citrate Anticoagulation (SARCA Study)

NCT06433193Not ApplicableCompleted

Early Feasibility Study to Evaluate the Safety and Efficacy of PAK HD in ESRD Patients

NCT05888376Completed

A Post-Market Clinical Performance and Safety Evaluation of GamCath HighFlow Dolphin Protect Catheter

NCT02278562Phase 2CompletedPrimary

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

Scroll to load more

Research Network

Activity Timeline